EUCTR2005-003836-22-ES进行中（未招募）1 期
Estudio de fase III, aleatorizado y en doble ciego, de galiximab en combinación con rituximab frente a rituximab en combinación con placebo en el tratamiento de sujetos con linfoma no Hodgkin folicular en recidiva o refractario
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •To be considered for registration and randomization into this study, subjects must satisfy all of the following criteria:
- •1. Must give written informed consent and any authorizations as required by local law
- •2. Aged =18 years old at the time of informed consent
- •3. Histologically confirmed follicular NHL Grade 1-3a (if the subject has received any intervening lymphoma therapy since the most recent biopsy, a repeat biopsy will be required to exclude transformation)
- •4. Relapsed or progressive disease after at least 1 chemotherapy requiring treatment as determined by one of the following:
- •- Documented disease progression by CT scan using the International Workshop Response Criteria (IWRC) as described in protocol Appendix C
- •- The presence of B symptoms
- •- Bulky disease (at least 1 lesion >5 cm)
- •- Laboratory abnormalities (cytopenias)
- •- Presence of masses which are causing ongoing clinical symptoms
- •5. Bidimensionally measurable disease with at least 1 lesion =2.0 cm in a single dimension
- •6. Hematologic, hepatic, and renal function parameters satisfying the following:
- •- Bilirubin =2.0 mg/dL
- •- AST (SGOT) =2 x upper limit of normal (ULN) and ALT (SGPT) = 2 x ULN
- •- Serum creatinine = 2.0 mg/dL
- •- Hemoglobin = 8.0 g/dL
- •- Absolute neutrophil count = 1500 cells/mm3
- •- Platelet count = 75,000 plts/mm3
- •7. WHO Performance Status = 2
- •8. Recovered fully from any significant toxicity associated with prior surgery, radiation treatments, chemotherapy, biological therapy, autologous bone marrow or stem cell transplant, or investigational drugs
- •9. Expected survival of = 3 months
- •10. Subjects of reproductive potential must agree to follow accepted birth control methods during treatment and for 12 months after completion of treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Unless otherwise specified, candidates will be excluded from study entry if any of the
- •following exclusion criteria exist at the time of randomization:
- •1. Follicular lymphoma Grade 3b
- •2. Previous exposure to galiximab or any anti-CD80 antibody
- •3. Known hypersensitivity to murine proteins
- •4. Rituximab refractory or refractory to anti-CD20 radioimmunotherapy (no response to prior rituximab or prior rituximab-containing regimen, or a response with a TTP of less than 6 months)
- •5. Cancer radiotherapy, biological therapy, or chemotherapy within 3 weeks prior to
- •Study Day 1 (6 weeks if nitrosourea or mitomycin-C)
- •6. Prior lymphoma vaccine therapy within 12 months prior to Study Day 1
- •7. Chronic or intermittent corticosteroids for inflammatory or autoimmune disorders within 3 weeks prior to Study Day 1
- •8. Prior antibody therapy for lymphoma (including radioimmunotherapy) within 6 months
- •prior to Study Day 1
- •9. Autologous bone marrow or stem cell transplant within 6 months prior to Study Day 1
- •10. Prior allogeneic transplant
- •11. Transfusion-dependent subjects
- •12. Known history of hepatitis or hepatic disease. (Although testing for hepatitis B is not mandatory, this should be considered for all subjects considered at high risk for hepatitis B infection and in endemic areas. Subjects with any serological evidence of current or past hepatitis B exposure should be excluded unless the serological findings are clearly due to vaccination.)
- •13. Presence of chronic lymphocytic leukemia (CLL), marginal zone lymphoma,
- •mucosa-associated lymphoid tissue (MALT)
- •14. Presence of central nervous system (CNS) lymphoma
- •15. Known history of HIV infection or AIDS
- •16. Prior diagnosis of aggressive NHL or mantle-cell lymphoma
- •17. Histologic transformation
- •18. Presence of pleural or peritoneal effusion with positive cytology for lymphoma
- •19. Another primary malignancy requiring active treatment (except hormonal therapy)
- •20. Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions, which would compromise protocol objectives in the opinion of the Investigator and/or the Sponsor
- •21. New York Heart Association Class III or IV cardiac disease or myocardial infarction
- •within 6 months prior to Study Day 1
- •22. Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1
- •23. History of alcoholism or substance abuse within the 2 years prior to Study Day 1
- •24. Pregnant or currently breastfeeding
研究者
相似试验
进行中（未招募）
1 期
Estudio de fase III, aleatorizado y en doble ciego, de evaluación de la eficacia y la seguridad de sorafenib en comparación con placebo en el cáncer de tiroides diferenciado refractario al yodo radiactivo localmente avanzado/metastáticoA Double-Blind, Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid CancerCancer diferenciado de TiroidesDifferentiated thyroid cancerMedDRA version: 12.0Level: LLTClassification code 10016935Term: Follicular thyroid cancerMedDRA version: 12.0Level: LLTClassification code 10033701Term: Papillary thyroid cancerMedDRA version: 12.0Level: LLTClassification code 10055107Term: Thyroid cancer metastaticMedDRA version: 12.0Level: LLTClassification code 10066136Term: Huerthle cell carcinomaEUCTR2009-012007-25-ESBayer HealthCare AG380
进行中（未招募）
不适用
Estudio en fase III, aleatorizado, doble ciego, controlado con placebo y multicéntrico sobre la eficacia y la seguridad de cuatro ciclos de tratamiento de 12 semanas (48 semanas) con epratuzumab en pacientes con lupus eritematoso sistémico moderado a intenso (EMBODY2). - EMBODY 2upus Sistémico EritematosoMedDRA version: 12.1Level: LLTClassification code 10042945Term: Systemic lupus erythematosusEUCTR2010-018565-26-ESCB Inc.780
进行中（未招募）
不适用
Estudio en fase III, aleatorizado, doble ciego, controlado con un grupo paralelo con tratamiento activo para evaluar la eficacia y seguridad de BI 10773 en comparación con glimepirida administrados por vía oral durante 104 semanas en pacientes con diabetes mellitus de tipo 2 en tratamiento con metformina pero con un control glucémico insuficiente.A phase III randomised, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment.Diabetes mellitus de tipo 2 en tratamiento con metformina.Type 2 diabetes mellitus pre-treated with metforminMedDRA version: 12.1Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusEUCTR2009-016244-39-ESBoehringer Ingelheim España S.A1,400
进行中（未招募）
不适用
Estudio en Fase III, aleatorizado, doble ciego, controlado con placebo para investigar la eficacia y seguridad de Progesterona en pacientes con Traumatismo Craneoencefálico SeveroEUCTR2010-018283-16-ESBHR Pharma, LLC1,180
进行中（未招募）
1 期
Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatitis A como control en la prevención de la infección cervical persistente por el HPV-16 o HPV-18 y del cáncer de cérvix, administrada por vía intramuscular conforme a la pauta de vacunación 0, 1 y 6 meses, en mujeres sanas entre 15 y 25 añosA phase III, double-blind, randomized, controlled study to evaluate the efficacy of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine compared to hepatitis A vaccines as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy female subjects aged 15 – 25 years or age. - HPV-008cervical cancer => study is conducted in healthy femaleEUCTR2004-001325-14-ESGlaxoSmithKline SA18,644